trending Market Intelligence /marketintelligence/en/news-insights/trending/gbltbls9duzq0a-dm25cra2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Gilead CEO's total compensation rises to $15.4M in 2017

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Gilead CEO's total compensation rises to $15.4M in 2017

Gilead Sciences Inc. paid President and CEO John Milligan about $15.4 million in total remuneration during 2017, up from about $13.9 million in 2016.

Milligan pocketed almost $1.55 million in base salary and $3.24 million in bonus payments, the company stated in a filing to the U.S. Securities and Exchange Commission.

That compares to $1.5 million in base salary and $2.61 million in bonus payments in 2016.

The California-based pharmaceutical giant's CEO received $4.89 million from stock awards and almost $5.75 million from option awards in 2017. In 2016, Milligan received about $4.35 million from stock awards and about $5.5 million from option awards.

Gilead's compensation committee had previously approved equity awards worth $11.5 million for Milligan in 2017 at its February 2017 meeting, compared to $11 million the previous year.

The ratio of Milligan's annual total compensation compared to Gilead's median employee's total annual compensation for fiscal year 2017 is 94 to 1.